Pegvisomant

Hyperbilirubinaemia and drug-induced liver injury: 2 case reports

    This is a preview of subscription content, access via your institution.

    Reference

    1. Yamaguchi H, et al. Long-term safety and treatment outcomes of pegvisomant in Japanese patients with acromegaly: results from the post-marketing surveillance. Endocrine Journal 67: 201-210, No. 2, 28 Feb 2020. Available from: URL: http://doi.org/10.1507/endocrj.EJ19-0266

    Download references

    Rights and permissions

    Reprints and Permissions

    About this article

    Verify currency and authenticity via CrossMark

    Cite this article

    Pegvisomant. Reactions Weekly 1839, 250 (2021). https://doi.org/10.1007/s40278-021-90088-4

    Download citation